Cargando…

RAS testing in metastatic colorectal cancer: advances in Europe

Personalized medicine shows promise for maximizing efficacy and minimizing toxicity of anti-cancer treatment. KRAS exon 2 mutations are predictive of resistance to epidermal growth factor receptor-directed monoclonal antibodies in patients with metastatic colorectal cancer. Recent studies have shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Krieken, J Han JM, Rouleau, Etienne, Ligtenberg, Marjolijn J. L., Normanno, Nicola, Patterson, Scott D., Jung, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Review and Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830882/ https://www.ncbi.nlm.nih.gov/pubmed/26573425 http://dx.doi.org/10.1007/s00428-015-1876-7

Ejemplares similares

RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers
por: Boleij, Annemarie, et al.
Publicado: (2015)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
por: Han van Krieken, J., et al.
Publicado: (2017)

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres
por: Boleij, Annemarie, et al.
Publicado: (2016)

Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL
por: Deans, Zandra C, et al.
Publicado: (2016)

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review
por: Trojan, Jörg, et al.
Publicado: (2015)

Guidance for laboratories performing molecular pathology for cancer patients
por: Cree, Ian A, et al.
Publicado: (2014)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences
por: Normanno, Nicola, et al.
Publicado: (2015)

The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment
por: Dijkstra, Jeroen R., et al.
Publicado: (2015)

Acquiring experience in pathology predominantly from what you see, not from what you read: the HIPON e-learning platform
por: Riccioni, Olga, et al.
Publicado: (2015)

Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT)
por: Normanno, Nicola, et al.
Publicado: (2020)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer
por: Cha, Pu-Hyeon, et al.
Publicado: (2016)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Familial gastric cancer: detection of a hereditary cause helps to understand its etiology
por: Vogelaar, Ingrid P, et al.
Publicado: (2012)

KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting
por: Barone, Carlo, et al.
Publicado: (2014)

Improving calculation, interpretation and communication of familial colorectal cancer risk: Protocol for a randomized controlled trial
por: Dekker, Nicky, et al.
Publicado: (2010)

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue
por: Tol, Jolien, et al.
Publicado: (2010)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
por: Rachiglio, Anna Maria, et al.
Publicado: (2020)

EMAST Is Associated with a Poor Prognosis in Microsatellite Instable Metastatic Colorectal Cancer
por: Venderbosch, Sabine, et al.
Publicado: (2015)

Emerging RAS superfamily conditions involving GTPase function
por: Shieh, Joseph T. C.
Publicado: (2019)

Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?
por: Keppens, Cleo, et al.
Publicado: (2019)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
por: Koopman, M, et al.
Publicado: (2009)

Most Patients with Colorectal Tumors at Young Age Do Not Visit a Cancer Genetics Clinic
por: Overbeek, Lucia I. H., et al.
Publicado: (2008)

Personalized Medicine in Europe
por: Nimmesgern, E, et al.
Publicado: (2017)

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data
por: Kafatos, George, et al.
Publicado: (2017)

Ras functional proximity proteomics establishes mTORC2 as new direct ras effector
por: Kovalski, Joanna R., et al.
Publicado: (2019)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Emergence of Toscana Virus in Europe
por: Charrel, Rémi N., et al.
Publicado: (2005)

Alliance for biomedical research in Europe
por: Smith, Ulf, et al.
Publicado: (2011)

H-Ras gene takes part to the host immune response to COVID-19
por: Sciacchitano, Salvatore, et al.
Publicado: (2021)

Localized RAS signaling drives cancer
por: Basu, Sandip K., et al.
Publicado: (2019)

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Tackling Mantle Cell Lymphoma in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Scientific perspectives on lunar exploration in Europe
por: Flahaut, Jessica, et al.
Publicado: (2023)

Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line
por: Pudewell, Silke, et al.
Publicado: (2021)

Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qcjr8h2tjmgtq2j5uj55sn4fb3